Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Hatch/Waxman Fix Proposal Includes “Beefed-Up” Patent Declarations

This article was originally published in The Tan Sheet

Executive Summary

FDA is considering requiring innovator companies to provide more information about patents they file for listing in the Orange Book as one way of addressing Hatch/Waxman loopholes

You may also be interested in...

FTC Backs Single 30-Month Stay On Generic Approvals In Patent Litigation

The Federal Trade Commission supports a limit of one 30-month stay of approval on generic drugs in patent litigation

Senate Generic Drug Bill Would Allow Challenges To Orange Book Listings

The amended version of the McCain/Schumer generic drug legislation would allow generic companies to sue patent holders for not providing correct and complete information about Orange Book listings

FDA Review Standards “Inconsistent” For New Drugs, Generics, PhRMA Says

The lack of an integrated review staff for new drugs and generics has led to "inconsistent" review standards between new drug divisions and the Office of Generic Drugs, the Pharmaceutical Research & Manufacturers of America says in a "white paper" submitted to FDA

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts